Synthorx (Synthorx) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Synthorx Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Synthorx's annualized Gross Profit for the quarter that ended in Sep. 2019 was $0.00 Mil. Synthorx's average Total Assets over the quarter that ended in Sep. 2019 was $168.53 Mil. Therefore, Synthorx's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2019 was 0.00%.

Synthorx Gross-Profit-to-Asset % Historical Data

The historical data trend for Synthorx's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Gross-Profit-to-Asset % Chart

Synthorx Annual Data

Trend

Dec16

Dec17

Dec18

Gross-Profit-to-Asset %

Synthorx Quarterly Data
	Dec16	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Synthorx's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Synthorx's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synthorx's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Synthorx's Gross-Profit-to-Asset % falls into.

Synthorx Gross-Profit-to-Asset % Calculation

Synthorx's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2018 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2018 )	/	( (Total Assets (A: Dec. 2017 )	+	Total Assets (A: Dec. 2018 ))	/ count )
	=	0	/	( (4.469	+	191.506)	/ 2 )
	=	0	/	97.9875
	=	0.00 %

Synthorx's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2019 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2019 )	/	( (Total Assets (Q: Jun. 2019 )	+	Total Assets (Q: Sep. 2019 ))	/ count )
	=	0	/	( (173.393	+	163.671)	/ 2 )
	=	0	/	168.532
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2019) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Synthorx Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Synthorx's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synthorx (Synthorx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037

Website

http://www.synthorx.com

Executives

Powell Andrew Kenneth William	director	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver	director, officer: President and CEO	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022